Key Takeaways From Crescent Capital BDC Analyst Ratings
Portfolio Pulse from Benzinga Insights
Crescent Capital BDC (NASDAQ:CCAP) has received mixed analyst ratings over the past quarter, with two analysts being somewhat bullish and two indifferent. The average 12-month price target has increased to $18.75 from $17.75. Analysts from Wells Fargo, Keefe, Bruyette & Woods, and Raymond James have raised their price targets, reflecting positive sentiment. Despite high debt levels, Crescent Capital BDC shows strong revenue growth, net margin, ROE, and ROA.
July 26, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crescent Capital BDC has received mixed analyst ratings, with an increased average 12-month price target to $18.75. Analysts from Wells Fargo, Keefe, Bruyette & Woods, and Raymond James have raised their price targets, indicating positive sentiment. The company shows strong revenue growth and profitability metrics, despite high debt levels.
The increase in the average price target and the positive sentiment from multiple analysts suggest a likely short-term price increase. The company's strong financial performance, despite high debt levels, further supports this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100